molecule.one logo — Autoresearch for chemistry

molecule.one

Autoresearch for chemistry

Founded 2019 United States San Francisco, United States 37 employees Seed Total: $4.99M AI, Pharmaceutical

General Information

Company Name molecule.one
Founded Year 2019
Location United States San Francisco, United States
Employees 37
Industries AI, Pharmaceutical
Funding Stage Seed
Business Model B2B, SaaS, D2C
Revenue Model Licensing, Service Fee, Product Sales
Offices as of Sep 2026
San Francisco, United States Warsaw, Poland
Social

BounceWatch is an independent company data service, not affiliated with molecule.one. To contact molecule.one, visit molecule.one.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does molecule.one compare?

A PDF of molecule.one and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting molecule.one soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Grant Received Oct 01, 2026

molecule.one received $1M from Standard Industries by winning their Challenge for retrosynthesis system research.

Homepage Update

Significant changes detected on company website (74.2% content change).

Certification Sep 30, 2026

molecule.one had its first patent for AI in synthesis planning granted in Japan on September 30, 2026.

Growth Metrics Sep 29, 2026

Molecule.one has achieved more than 500,000 experiments run in their AI-powered lab since 2022.

About molecule.one

molecule.one is an innovative startup operating at the intersection of AI and Pharmaceutical industries. Founded in 2019 and headquartered in the United States, the company is leveraging artificial intelligence and data-driven approaches to design creative and accurate chemical syntheses.

Aligning with its slogan, "Autoresearch for chemistry", molecule.one offers a unique service that enables ordering of custom molecules with rapid delivery, thereby accelerating the process from novel hits to practical applications. Their service promises delivery within a week and novel hits in just four weeks, showcasing a strong commitment to speed and efficiency.

In its last known funding activity, molecule.one secured a $4.60M Seed Round investment on 01 June 2021. This investment round was led by a diverse group of investors including AME Cloud Ventures, Cherubic Ventures, and Sunfish Partners, among others, underscoring robust investor confidence in the company’s strategic direction and potential impact on the market.

Taxonomy: artificial_intelligence, chemical_synthesis, molecule_design, preclinical_pipeline, information_technology, bioinformatics, computational_chemistry, data_science, bench_chemistry, drug_discovery, innovative_solutions, novel_molecule_delivery, chemistry_tools

Services & Products

Robotic High-Throughput Synthesis
AI-Powered Chemical Reaction Mapping
On-Demand Molecule Delivery
Licensing of Synthesis Platform

Target Customers

Pharmaceutical Companies Biotechnology Firms Chemical Researchers CROs (Contract Research Organizations)

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $4.60M 8
AME Cloud Ventures, Cherubic Ventures +6
01 Jun 2021
Pre Seed Round $250.00K 2
Possible Ventures, Sunfish Partners
19 Aug 2019
Pre Seed Round $135.00K -
31 May 2019

molecule.one Alternatives & Competitors

View All Alternatives
molecule.one vs
iktos
iktos France

Artificial intelligence for new drug design

Series A
85 employees
AI, Biotechnology
molecule.one vs
Ainnocence
Ainnocence United States

AI For Better Medicine

Seed
12 employees
AI, Biotechnology
molecule.one vs
Menten AI
Menten AI United States

Unlocking the potential of peptides macrocycles to create tomorrow's life-changing medicines with Ge...

Seed
19 employees
AI, Biotechnology

FAQ About molecule.one

Autoresearch for chemistry
molecule.one was founded in 2019.
molecule.one is headquartered in San Francisco, United States. As of Sep 2026, it also has offices in Warsaw, Poland.
molecule.one operates in AI and Pharmaceutical. Its work centres on artificial_intelligence, chemical_synthesis, molecule_design and preclinical_pipeline. Its customers include Pharmaceutical Companies, Biotechnology Firms and Chemical Researchers.
molecule.one has a B2B, SaaS and D2C business model. Its revenue comes from Licensing, Service Fee and Product Sales.
molecule.one has approximately 37 employees.
molecule.one has completed 3 funding rounds, raising a total of $4.99M. The latest funding stage is Seed.
molecule.one offers: Robotic High-Throughput Synthesis, AI-Powered Chemical Reaction Mapping, On-Demand Molecule Delivery, Licensing of Synthesis Platform.
Top alternatives and competitors to molecule.one include iktos, Ainnocence, Menten AI, Atomwise, Hafnium Labs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
molecule.one and iktos are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for molecule.one, https://bouncewatch.com/company/moleculeone, updated 18 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes